What is PEN (PEN) stock price today?

PEN (PEN) is currently trading at $320.33, up 0.26% today.

What is PEN P/E ratio?

PEN's P/E ratio is 72.38. This is above the market average, reflecting high growth expectations.

What is PEN return on equity (ROE)?

PEN's return on equity (ROE) is 12.46%, indicating how efficiently the company generates profit from shareholders' equity. This is above the market average.

What is PEN's market cap?

PEN has a market capitalization of $12.60B.

NYSE · Medical - Devices

PEN (PEN) Stock

$320.33 +0.26% NYSE: PEN Healthcare

Valuation

Metric	Value
Price	$320.33
Market Cap	$12.60B
P/E Ratio	72.38
P/B Ratio	9.01
P/S Ratio	8.83
EPS (TTM)	$4.52
52-Week High	$362.41
52-Week Low	$221.26
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	12.46%
ROA	9.74%
ROCE	13.24%
Gross Margin	13.53%
Operating Margin	13.46%
Net Margin	11.76%
Debt/Equity	0.15
Current Ratio	6.65

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$748.0M	$847.0M	$1.1B	$1.2B	$1.4B
Operating Profit	$-8.0M	$6.0M	$74.0M	$9.0M	$189.0M
Net Profit	$5.0M	$-2.0M	$91.0M	$14.0M	$178.0M
EPS	$0.14	$-0.05	$2.32	$0.36	$4.52
Op Margin	-1.0%	0.7%	7.0%	0.8%	13.5%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$1.2B	$1.4B	$1.6B	$1.5B	$1.8B
Total Liabilities	$290.0M	$372.0M	$377.0M	$382.0M	$399.0M
Cash	$59.0M	$70.0M	$167.0M	$324.0M	$187.0M
Borrowings	$174.0M	$236.0M	$234.0M	$223.0M	$220.0M

Latest News

THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care PR Newswire · Jul 22, 2026 PEN: Raising target price to $349.00 Argus Research · Jul 22, 2026 3 Medical Device Stocks Giving Investors a Different Healthcare Play MarketBeat · Jul 20, 2026 IQV vs. PEN: Which Stock Is the Better Value Option? Zacks · Jul 14, 2026 First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke PR Newswire · Jul 7, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$10.0M	$-56.0M	$97.0M	$168.0M	$239.0M
Investing Cash Flow	$-43.0M	$35.0M	$-31.0M	$56.0M	$-468.0M
Financing Cash Flow	$-16.0M	$-8.0M	$-2.0M	$-85.0M	$-3.0M
Net Cash Flow	$-10.0M	$10.0M	$98.0M	$157.0M	$-138.0M
Free Cash Flow	$-12.0M	$-75.0M	$82.0M	$147.0M	$175.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	62.63
FCF Yield	1.66%
Quick Ratio	3.95
Interest Coverage	—
Return 1Y	38.68%
Return 3Y	4.55%
Return 5Y	18.81%

Ownership

Insiders Held2.90%

Institutions Held87.07%

Institutions Float Held89.67%

Institutional Holder	Shares	Report Date
Blackrock Inc.	4,330,456	2026-03-31
Vanguard Capital Management LLC	1,694,488	2026-03-31
Vanguard Portfolio Management LLC	1,654,477	2026-03-31
HBK Investments L P	1,634,261	2026-03-31
State Street Corporation	1,185,811	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ALGNAlign Technology, Inc.	$169.29	+1.36%	27.86	$12.12B	0.00%
BAXBaxter International Inc.	$23.18	+3.46%	11.25	$11.97B	0.88%
BIO	$330.54	+4.47%	10.29	$8.94B	0.00%
CRL	$232.51	-0.90%	-54.59	$11.20B	0.00%
DVADaVita Inc.	$236.58	+0.48%	23.20	$15.18B	0.00%

About PEN

PEN is led by CEO Adam Elsesser, employs 4,700 people, headquartered in Alameda, US, publicly traded since 2015.

PEN stock trades at $320.33 with a market capitalization of $12.60B. The stock is valued at a price-to-earnings (P/E) ratio of 72.38, price-to-book of 9.01, price-to-sales of 8.83. Over the past 52 weeks the stock has ranged between $221.26 and $362.41, and currently trades 11.6% below its 52-week high.

On profitability, PEN generates a return on equity (ROE) of 12.46%, above the typical market average, return on capital employed of 13.24%, an operating margin of 13.46%, a net profit margin of 11.76%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks NYSE High ROE Stocks All stock screens

Run Stock Screener Investing Guides